AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Debating Maintenance Therapy Options for High-Risk Multiple Myeloma Patients
The chapter delves into the debate surrounding maintenance therapy for high-risk multiple myeloma patients, weighing options like carfilzomib and lenalidomide long-term versus just lenalidomide. The speakers discuss data from various trials, challenges in decision-making, and the importance of continuous therapy for high-risk patients. They touch on ongoing trials exploring the role of different agents in maintenance therapy and emphasize the need for personalized treatment approaches in myeloma care.